account_id none on file
legal_name Foghorn Therapeutics Inc.
ticker FHTX
cik 1822462
domain foghorntx.com
linkedin_company_url https://www.linkedin.com/company/foghorn-therapeutics/
entry_point_account_id none on file
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 8 executives 0 family 0
why_nownone on file
callsnone on file
filings
The decrease is primarily attributed to a decrease in facilities and IT related expenses and other costs of $0.5 million primarily driven by a reduction in rent and building maintenance costs associated with the Company’s new office lease in Watertown, Massachusetts.
filing / Aug 6, 2026 / receipt
The decrease is primarily attributed to a decrease in facilities and IT related expenses and other costs of $1.0 million primarily driven by a reduction in rent and building maintenance costs associated with the Company’s new office lease in Watertown, Massachusetts.
filing / Aug 6, 2026 / receipt
Future annual minimum lease payments under the Office Lease as of June 30, 2026 were as follows (in thousands): Remainder of 2026 (six months) $ 979 2027 4,280 2028 5,713 2029 6,774 2030 6,977 Thereafter 36,088 Total future minimum lease payments 60,811 Less: imputed interest ( 17,709 ) Total operating lease liabilities $ 43,102 Included in the consolidated balance sheets (in thousands): June 30,
filing / Aug 6, 2026 / receipt
The Company leases laboratory and office space under a non-cancelable operating lease (the “Operating Lease”). There have been no material changes to the Company's Operating Lease during the three and six months ended June 30, 2026.
filing / Aug 6, 2026 / receipt
The decrease is primarily attributed to a decrease in facilities and IT related expenses and other costs of $0.5 million primarily driven by a reduction in rent and building maintenance costs associated with the Company’s new office lease in Watertown, Massachusetts.
filing / May 7, 2026 / receipt
• a decrease in facilities and IT related expenses and other costs of $2.0 million primarily driven by a reduction in rent and building maintenance costs associated with the Company’s new office lease in Watertown, Massachusetts; and
filing / May 7, 2026 / receipt
Future annual minimum lease payments under the Office Lease as of March 31, 2026 were as follows (in thousands): Remainder of 2026 (nine months) $ 979 2027 4,280 2028 5,713 2029 6,774 2030 6,977 Thereafter 36,088 Total future minimum lease payments 60,811 Less: imputed interest ( 18,453 ) Less: lease incentives ( 364 ) Total operating lease liabilities $ 41,994 Included in the consolidated bal
filing / May 7, 2026 / receipt
The Company leases laboratory and office space under a non-cancelable operating lease (the “Operating Lease”). There have been no material changes to the Company's Operating Lease during the three months ended March 31, 2026.
filing / May 7, 2026 / receipt
executivesnone on file
familynone on file
upcoming
| 2026-11-04 | earnings call | scheduled | ir |
changesnone on file
mcp_package_hint
slug foghorn-therapeutics-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$